Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
Pediatr Infect Dis J. 2012 Apr;31(4):373-8. doi: 10.1097/INF.0b013e3182481ef8.
Novel 2009/H1N1 influenza has significant impact on immunocompromised children with cancer; however, it is uncertain how it compares with seasonal influenza (SFlu) in this vulnerable population. We compared clinical characteristics and outcomes for these 2 infections in children with cancer and identified risk factors for progression to lower respiratory infection (LRI) and/or death.
Influenza infections confirmed by positive viral culture and/or fluorescence antigen test between January 1998 and February 2010 were identified from microbiology databases at a comprehensive cancer center. Characteristics and outcomes were compared for the 2 groups. Kaplan-Meier survival curves and Cox proportional hazards model were generated to identify risk factors for LRI and/or death.
When compared with SFlu, 2009/H1N1 cases had significantly lower acute physiology and chronic health evaluation II score (median: 9 versus 14), fewer comorbidities (15% versus 46%), fewer hematopoietic stem-cell transplantation (5% versus 16%), more solid tumors (45% versus 16%), higher LRI at presentation (20% versus 4%), higher rates of antiviral therapy (90% versus 48%) and higher mortality (10% versus 0%). Male gender (hazard ratio [HR]: 8.4, 95% confidence interval [CI]: 1.08-65.2, P = 0.042), acute physiology and chronic health evaluation II score > 15 (HR: 3.29, 95% CI: 1.04-10.39, P = 0.027) and a 24-hour delay in initiation of antiviral treatment (HR: 1.12, 95% CI: 1.02-1.23, P = 0.015) were the most significant predictors of progression to LRI and mortality, regardless of virus strain.
Significant differences between 2009/H1N1 and SFlu with respect to clinical presentation, management and associated outcomes were identified. Early diagnosis and prompt initiation of antiviral therapy may prevent serious complications of influenza in children with cancer.
新型 2009/H1N1 流感对患有癌症的免疫功能低下的儿童有重大影响;然而,在这一脆弱人群中,其与季节性流感(SFlu)的比较情况尚不确定。我们比较了癌症患儿中这两种感染的临床特征和结局,并确定了向下呼吸道感染(LRI)和/或死亡进展的危险因素。
从综合癌症中心的微生物学数据库中确定了 1998 年 1 月至 2010 年 2 月间经病毒培养和/或荧光抗原检测阳性确诊的流感感染病例。比较了两组患者的特征和结局。通过 Kaplan-Meier 生存曲线和 Cox 比例风险模型确定 LRI 和/或死亡的危险因素。
与 SFlu 相比,2009/H1N1 病例的急性生理学和慢性健康评估 II 评分明显较低(中位数:9 分比 14 分),合并症较少(15%比 46%),造血干细胞移植更少(5%比 16%),实体瘤更多(45%比 16%),就诊时 LRI 更高(20%比 4%),抗病毒治疗的比例更高(90%比 48%),死亡率更高(10%比 0%)。男性(危险比 [HR]:8.4,95%置信区间 [CI]:1.08-65.2,P=0.042)、急性生理学和慢性健康评估 II 评分>15 分(HR:3.29,95% CI:1.04-10.39,P=0.027)和抗病毒治疗开始延迟 24 小时(HR:1.12,95% CI:1.02-1.23,P=0.015)是 LRI 和死亡进展的最重要预测因素,与病毒株无关。
确定了 2009/H1N1 与 SFlu 在临床表现、治疗和相关结局方面的显著差异。早期诊断和及时开始抗病毒治疗可能预防癌症患儿流感的严重并发症。